Computer modeling shows how medications play a part in the Parkinson's experience

September 11, 2012, University of Western Sydney

(Medical Xpress)—A University of Western Sydney researcher has developed a new computational model, which will improve our understanding of how Parkinson's disease (PD) medications affect the brain and cognition.

Dr Ahmed Moustafa, from the School of Social Sciences and Psychology and the MARCS Institute at UWS, says the primary symptoms of PD are thought to be the result of the insufficient formation and action of Dopamine.

"Dopamine is one of the neurotransmitters responsible for the way the human brain processes information," says Dr Moustafa.

"When Parkinson's patients experience symptoms of motor skill and cognitive dysfunction – such as muscle rigidity, tremors and a slowing of physical movement – it is believed that the disease has impaired the ability of their brains to produce this important chemical that led to the motor and ."

Along with colleagues Dr Mohammad Herzallah and Dr Mark Gluck from the Center for Neuroscience at Rutgers University, Dr Moustafa has devised a method of tracking the various affects of key Dopamine replacement therapies – such as Levodopa, and Ropinirole.

The 'computational model', to be published in the journal, provides a mechanistic account of several positive and negative effects of PD treatments.

Dr Moustafa says the key effect appears to lie within the activation of the D1 and D2 receptors.

"It appears that that the differential effects of dopamine medications are related to their binding to D1 and D2 receptors. It seems that these medications have variable effects on D1 receptors," says Dr Moustafa.

"By tracking how these different treatments affect different , we have been able to explain why some PD patients experience some very different ."

Dr Moustafa says treatments such as Levodopa, which produce added Dopamine by over stimulating the motor neurons, appear to have a higher affinity with these D1 receptors.

"Clinical research shows that the chronic administration of Levodopa can enhance ' cognition, but can also lead to a phenomenon known as Levodopa-induced Dyskinesia – a disorder which causes patients to have involuntary movements, most commonly in the upper body," he says.

"Other treatments, which do not activate the D1 receptors, do not have the same effects."

Dr Moustafa's will have wide-ranging implications for understanding the varied physical effects of Parkinson's disease, as well as the potential side-effects of Parkinson's medications.

"Clinical research also shows that a subset of Parkinson's patients develops what is known as impulse control disorders, which involve pathological gambling, hypersexuality, and binge eating," says Dr Moustafa.

"Basically, the brain's difficulty in processing information eventually impairs the patient's ability to learn to avoid negative outcomes – including gaining weight, and losing jobs, money and relationships.

"If the development of these impulse control disorders can be conclusively traced to the overstimulation of , it may be possible to understand why some Parkinson's patients develop impulse control disorders, and others do not – and then to regulate the medications that stimulate these specific receptors."

Related Stories

Recommended for you

Investigators eye new target for treating movement disorders

January 19, 2018
Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson's disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.

Parkinson's disease 'jerking' side effect detected by algorithm

January 8, 2018
A mathematical algorithm that can reliably detect dyskinesia, the side effect from Parkinson's treatment that causes involuntary jerking movements and muscle spasms, could hold the key to improving treatment and for patients ...

New brainstem changes identified in Parkinson's disease

January 4, 2018
A pioneering study has found that patients with Parkinson's disease have more errors in the mitochondrial DNA within the brainstem, leading to increased cell death in that area.

Caffeine level in blood may help diagnose people with Parkinson's disease

January 3, 2018
Testing the level of caffeine in the blood may provide a simple way to aid the diagnosis of Parkinson's disease, according to a study published in the January 3, 2018, online issue of Neurology, the medical journal of the ...

Researchers shed light on why exercise slows progression of Parkinson's disease

December 22, 2017
While vigorous exercise on a treadmill has been shown to slow the progression of Parkinson's disease in patients, the molecular reasons behind it have remained a mystery.

Robotic device improves balance and gait in Parkinson's disease patients

December 19, 2017
Some 50,000 people in the U.S. are diagnosed with Parkinson's disease (PD) every year. The American Institute of Neurology estimates there are one million people affected with this neurodegenerative disorder, with 60 years ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.